Nitroglycerin 2 mg Sustained Release Buccal Tablet
RxNorm 312016
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 312016 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: nitroglycerin 2 mg Sustained Release Buccal Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCD
Semantic Clinical Drug (SCD):
Nitroglycerin 2 mg Sustained Release Buccal Tablet
(Atom ID: 12340531)
SY
Synonym (SY):
Glyceryl trinitrate 2 mg prolonged-release buccal tablet
(Atom ID: 11436903)
PT
Designated preferred name (PT):
Nitroglycerin 2 mg prolonged-release buccal tablet
(Atom ID: 11437783)
PSN
Prescribable Name (PSN):
Nitroglycerin 2 mg Sustained Release Buccal Tablet
(Atom ID: 6365442)
SY
Synonym (SY):
NTG 2 mg Sustained Release Buccal Tablet
(Atom ID: 3851176)
FN
Full form of descriptor (FN):
Product containing precisely glyceryl trinitrate 2 mg/1 each prolonged-release buccal tablet (clinical drug)
(Atom ID: 11440001)
SY
Synonym (SY):
TNG 2 mg Sustained Release Buccal Tablet
(Atom ID: 3851175)
Patient Education
Nitroglycerin Sublingual
Nitroglycerin sublingual tablets are used to treat episodes of angina (chest pain) in people who have coronary artery disease (narrowing of the blood vessels that supply blood to the heart). It is also used just before activities that may cause episodes of angina in order to prevent the angina from occurring. Nitroglycerin is in a class of medications called vasodilators. It works by relaxing the blood vessels so the heart does not need to work as hard and therefore does not need as much oxygen.
[Learn More]
* Please review the disclaimer below.